BioPartnering Europe, London, October 2011
Tuesday, 25 October 2011
Partnering is absolutely central to the way that we’re approaching the development of patient stratification tools and companion diagnostics and we have a very open approach to collaboration. We simply want to work with the best biotech companies, the best academic centres, the best diagnostic companies that will help us deliver important new medicines to improve the outcome for patients.
AstraZeneca had a high profile at a recent business partnering event in Europe – sowing the seeds for future deals and supporting our externalisation efforts going forward. There were around 500 delegates at the BioPartnering Europe conference which took place in London from October 9-11.
The keynote presentation by Bob Holland, AstraZeneca VP Personalised Healthcare and Biomarker Support, reinforced how partnership and collaboration are at the core of AstraZeneca’s personalised healthcare strategy. Entitled “The Search for Innovation in Healthcare: Companion diagnostics are the new frontier”, Bob’s talk highlighted our determination to enhance innovation through personalised healthcare and through partnering. Emphasising our ambition to become the preferred partner of choice, Bob explained how no single partner can address all of our PHC needs so we are looking for a series of partnerships to help us to achieve our aims.
Dr Bob Holland, AstraZeneca VP Personalised Healthcare and Biomarker Support, talks about our Personalised Healthcare strategy and how it has partnering absolutely at the heart of the way that we’re approaching the creation of new stratified medicines.